Kore Private Wealth’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
$797K Buy
2,465
+15
+0.6% +$4.75K 0.14% 97
2022
Q2
$794K Sell
2,450
-581
-19% -$174K 0.12% 117
2022
Q1
$868K Sell
3,031
-170
-5% -$43.8K 0.11% 131
2021
Q4
$884K Buy
3,201
+38
+1% +$9.63K 0.11% 126
2021
Q3
$731K Sell
3,163
-252
-7% -$62.2K 0.08% 191
2021
Q2
$784K Sell
3,415
-1,047
-23% -$210K 0.09% 166
2021
Q1
$834K Sell
4,462
-130
-3% -$25.4K 0.11% 126
2020
Q4
$775K Buy
4,592
+375
+9% +$56K 0.12% 119
2020
Q3
$624K Buy
4,217
+137
+3% +$21.2K 0.12% 120
2020
Q2
$669K Sell
4,080
-32
-0.8% -$4.91K 0.14% 108
2020
Q1
$570K Buy
4,112
+465
+13% +$63.9K 0.14% 106
2019
Q4
$479K Buy
3,647
+95
+3% +$11K 0.09% 142
2019
Q3
$394K Buy
3,552
+128
+4% +$14.3K 0.09% 147
2019
Q2
$379K Buy
3,424
+20
+0.6% +$2.35K 0.09% 151
2019
Q1
$442K Sell
3,404
-306
-8% -$37.2K 0.1% 133
2018
Q4
$429K Buy
+3,710
New +$414K 0.12% 134

Other funds holding LLY

Kore Private Wealth's LLY Position: Q3 2022 in Review

Kore Private Wealth increased its Eli Lilly (LLY) stake by 0.61% in Q3 2022, buying an estimated $4.75K and bringing the position to 2,465 shares worth $797K. The position accounts for 0.14% of the portfolio, ranked #97.

Kore Private Wealth first reported a position in LLY in Q4 2018 and has held it in 16 quarters since. The position peaked at $884K in Q4 2021. 2,485 funds tracked by Wall St. Rank hold LLY as of Q3 2022.

  • Kore Private Wealth held 2,465 shares of Eli Lilly worth $797K as of Q3 2022.
  • Kore Private Wealth bought 15 Eli Lilly shares in Q3 2022, an estimated $4.75K.
  • Eli Lilly made up 0.14% of Kore Private Wealth's portfolio in Q3 2022, its #97 holding.
  • Kore Private Wealth first reported a position in Eli Lilly in Q4 2018 and has held it in 16 quarters since.
  • Kore Private Wealth's Eli Lilly position peaked at $884K in Q4 2021.
  • 2,485 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.

Based on Kore Private Wealth's 13F filing for Q3 2022, filed 14 Nov 2022.